Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Anirban Maitra

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-7923-9978; OpenAlex author ID A5048073439, A5103921754; NIH RePORTER profile ID 7626839. Sources: funder_awards.

Their work

Papers
279 (first author 16, last author 30)
Trials
1 (principal investigator on 1)
Grants
21
Labs led
3
Collaborators
823
Papers, trials and grants by year

2004: 1 grant · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 14 papers · 2012: 16 papers, 1 grant · 2013: 5 papers, 1 grant · 2014: 7 papers, 4 grants · 2015: 15 papers · 2016: 16 papers, 1 grant · 2017: 25 papers, 1 grant · 2018: 16 papers · 2019: 28 papers · 2020: 23 papers, 1 grant · 2021: 19 papers, 1 trial, 2 grants · 2022: 19 papers, 1 grant · 2023: 14 papers, 2 grants · 2024: 24 papers, 1 grant · 2025: 12 papers, 1 grant · 2026: 26 papers, 4 grants

Papers 50 of 279

  1. Development and Validation of a Parsimonious Risk Stratification Model for Pancreatic Cancer. Co-author DOI 10.1001/jamaoncol.2026.0372↗
  2. Pancreatic Cancer-Advances in the Last 50 Years. First author DOI 10.1002/wjs.70309↗
  3. Pancreatic ductal adenocarcinoma: The Vision of Heracles. Co-author DOI 10.1016/j.ccell.2026.07.014↗
  4. Towards early detection of pancreatic cancer: The current status of cohort studies by the Diabetes-Pancreatic Ductal AdenoCarcinoma Working Group. Co-author DOI 10.1016/j.pan.2026.04.020↗
  5. Spatially resolved tissue architecture and computational pathology in pancreatic cancer. Last author DOI 10.1038/s12276-026-01782-4↗
  6. All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immunotherapy in pancreatic cancer. Co-author DOI 10.1038/s41467-026-72271-5↗
  7. Author Correction: Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Co-author DOI 10.1038/s41586-026-10995-6↗
  8. Author Correction: Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Co-author DOI 10.1038/s41586-026-11134-x↗
  9. Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer. Co-author DOI 10.1038/s41591-026-04537-w↗
  10. Machine learning-based multimodal biomarkers enable accurate diagnosis and early detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-025-29548-4↗
  11. CDK8 remodels the tumor microenvironment and promotes resistance to KRAS G12D inhibitors and daraxonrasib in PDAC. Co-author DOI 10.1038/s44318-026-00854-5↗
  12. Risk of Pancreatic Cancer in Glycemically Defined New-Onset Diabetes: A Prospective Cohort Study. Co-author DOI 10.1053/j.gastro.2025.06.025↗
  13. Heuriskance: a novel paradigm for systematic earlier detection of sporadic pancreatic cancer. Co-author DOI 10.1093/jnci/djaf291↗
  14. Phase I trial of binimetinib plus hydroxychloroquine in patients with previously treated metastatic pancreatic cancer. Co-author DOI 10.1093/oncolo/oyag071↗
  15. Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1093/oncolo/oyag423↗
  16. Clinicopathologic Characteristics of Brain Metastasis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/pas.0000000000002470↗
  17. KRAShing pancreatic cancer before takeoff. First author DOI 10.1126/science.aef6665↗
  18. Metastatic pancreatic cancer: from human disease to preclinical modelling. Last author DOI 10.1136/gutjnl-2025-336334↗
  19. Pancreatic Cancer KRAS Breakthrough: Drug Graveyard No More. Co-author DOI 10.1158/1078-0432.ccr-25-4177↗
  20. AI-Powered Deep Visual Proteomics Reveals Critical Molecular Transitions in Pancreatic Cancer Precursors. Last author DOI 10.1158/2159-8290.cd-25-1119↗
  21. Asynchronous Evolution of Epithelium and Stroma Differentiates Precursor Lesions from Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-25-2001↗
  22. The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/2767-9764.crc-25-0278↗
  23. CRISPR screen of human pancreatic cancer xenografts identifies a KLF5 proliferation vulnerability through epigenetic modifiers NCAPD2 and MTHFD1. Co-author DOI 10.1186/s12943-026-02575-z↗
  24. Extra-lineage tissue programs define the transcription states of human pancreatic cancer Co-author DOI 10.64898/2026.04.29.721655↗
  25. Assessment of impending pancreatic cancer in a cohort of new onset diabetes on basis of biomarker trajectory Co-author DOI 10.64898/2026.08.06.26359908↗
  26. KRAS-driven metabolic reprogramming of enhanced MFSD2A-mediated lysophosphatidylcholine scavenging promotes survival and progression of pancreatic ductal adeno… Co-author DOI 10.64898/2026.10.05.756824↗
  27. Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5191↗
  28. A Mixed-Methods Approach to Assessing Barriers and Facilitators to Cancer Genetics Care in Black and Latino/a Individuals Impacted by Pancreatic Cancer: The Ra… Co-author DOI 10.1007/s10620-025-09018-7↗
  29. Lead time trajectory of blood-based protein biomarkers for detection of pancreatic cancer based on repeat testing. Co-author DOI 10.1016/j.canlet.2025.217450↗
  30. Engineered exosomes with Kras G12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates. Co-author DOI 10.1038/s41467-025-63718-2↗
  31. Spatial mapping of transcriptomic plasticity in metastatic pancreatic cancer. Last author DOI 10.1038/s41586-025-08927-x↗
  32. TREM2 Depletion in Pancreatic Cancer Elicits Pathogenic Inflammation and Accelerates Tumor Progression via Enriching IL-1β+ Macrophages. Co-author DOI 10.1053/j.gastro.2025.01.244↗
  33. Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/oncolo/oyae182↗
  34. A spatial atlas of chemoradiation therapy in pancreatic cancer identifies cellular and microenvironmental determinants of persister populations Co-author DOI 10.1101/2025.06.20.660757↗
  35. Genetics and biology of pancreatic ductal adenocarcinoma. Co-author DOI 10.1101/gad.351863.124↗
  36. An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer. Last author DOI 10.1126/scitranslmed.adt5511↗
  37. Integrated Metabolomics and Spatial Transcriptomics of Cystic Pancreatic Cancer Precursors Reveals Dysregulated Polyamine Metabolism as a Biomarker of Progress… Co-author DOI 10.1158/1078-0432.ccr-24-2931↗
  38. KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13045-025-01696-0↗
  39. A rigorous multi-laboratory study of known PDAC biomarkers identifies increased sensitivity and specificity over CA19-9 alone. Co-author DOI 10.1016/j.canlet.2024.217245↗
  40. Big insights from small samples: uncovering the potential of EUS-guided FNAs in pancreatic cancer through predictive genomics and transcriptomics. First author DOI 10.1016/j.ebiom.2024.105380↗
  41. Blood-Based microRNA Biomarker Signature of Early-Stage Pancreatic Ductal Adenocarcinoma With Lead-Time Trajectory in Prediagnostic Samples. Co-author DOI 10.1016/j.gastha.2024.08.002↗
  42. Loss of p53 and SMAD4 induces adenosquamous subtype pancreatic cancer in the absence of an oncogenic KRAS mutation. Co-author DOI 10.1016/j.xcrm.2024.101711↗
  43. Early detection of pancreatic cancer and AI risk partitioning Co-author DOI 10.1016/s0140-6736(24)00690-1↗
  44. Targeting a chemo-induced adaptive signaling circuit confers therapeutic vulnerabilities in pancreatic cancer. Co-author DOI 10.1038/s41421-024-00720-w↗
  45. Nardilysin-regulated scission mechanism activates polo-like kinase 3 to suppress the development of pancreatic cancer. Co-author DOI 10.1038/s41467-024-47242-3↗
  46. TSG-6+ cancer-associated fibroblasts modulate myeloid cell responses and impair anti-tumor response to immune checkpoint therapy in pancreatic cancer. Co-author DOI 10.1038/s41467-024-49189-x↗
  47. The liver casts a wide NET for metastatic pancreatic cancer. Last author DOI 10.1038/s41591-024-03112-5↗
  48. Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-024-00505-0↗
  49. A Randomized Trial of Two Remote Health Care Delivery Models on the Uptake of Genetic Testing and Impact on Patient-Reported Psychological Outcomes in Families… Co-author DOI 10.1053/j.gastro.2024.01.042↗
  50. Genetic Deletion of Galectin-3 Inhibits Pancreatic Cancer Progression and Enhances the Efficacy of Immunotherapy. Co-author DOI 10.1053/j.gastro.2024.03.007↗

Trials 1

  1. Early Detection Initiative for Pancreatic Cancer Principal investigator NCT04662879↗

Grants 21

  1. Clinical Validation Center for Early Detection of Pancreatic Cancer U01CA200468↗
  2. Chronic Pancreatitis Clinical Research Consortium (CPCRC) Data Coordinating Center (CPCRC-DCC) U01DK108328↗
  3. PASSCODE (Pancreatic Adenocarcinoma Stromal Reprograming ConSortium COordination, Data Management and Education) U24CA274274↗
  4. TBEL Project 3 U54CA274371↗
  5. Core C-Computational Core P01CA117969↗
  6. The Texas-Louisiana Alliance to Study Chronic Pancreatitis, Diabetes and Pancreatic Cancer U01DK126365↗
  7. Administrative Core P50CA221707↗
  8. Wnt/?-catenin Signaling in Pancreatic Oncogenesis R01CA220236↗
  9. Core 2: Biospecimen/Pathology Core P50CA062924↗
  10. Translational Applications in an Animal Model of Pancreatic Cystic Neoplasm and Cancer R01CA218004↗
  11. Pancreatic Ductal Adenocarcinoma Translational Resource Center (PATReC) U24CA224020↗
  12. Imaging and Molecular Correlates of Progression in Cystic Neoplasms of the Pancreas U01CA196403↗
  13. Optimizing Biomarker Combinations for Pancreatic Cancer Early Detection AWARD pancan:2017-anirban-maitra-samir-hanash-optimizing-biomarker-combinations-for-pa
  14. Targeting Kras in Pancreatic Cancer R21CA199050↗
  15. Innovative Grant: Anirban Maitra (macrophage function in pancreatic cancer-associated diabetes) AWARD pancan:2014-anirban-maitra-mbbs-md-innovative-grant-anirban-maitra-macropha
  16. Developmental Signaling Pathways in Pancreatic Cancer R01CA113669↗
  17. The Johns Hopkins Cancer Nanotechnology Training Center R25CA153952↗
  18. Systemic Nanocurcumin for Pancreatic Cancer Therapy U54CA151838↗
  19. Zebrafish Core P01CA134292↗
  20. Targeting CDK5 in Pancreatic Cancer: Mechanistic and Preclinical Development R01CA134767↗
  21. Notch Signaling in Pancreas Cancer AWARD pancan:2004-anirban-maitra-md-notch-signaling-in-pancreas-cancer

Closest collaborators

The 25 strongest of 823 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Huamin Wang · 58 shared papers, 2014–2026 · strength 6.24
  2. Matthew H. G. Katz · 59 shared papers, 2014–2026 · strength 5.62
  3. Eugene Jon Koay · 39 shared papers, 2014–2026 · strength 4.70
  4. Robert A. Wolff · 40 shared papers, 2014–2026 · strength 4.22
  5. Suresh T. Chari · 14 shared papers, 1 shared trial, 1 shared grant, 2015–2026 · strength 3.56
  6. Michael P. Kim · 30 shared papers, 2017–2025 · strength 3.13
  7. Haoqiang Ying · 22 shared papers, 2017–2026 · strength 3.09
  8. Florencia M. McAllister · 22 shared papers, 2014–2026 · strength 2.94
  9. Jason B. Fleming · 36 shared papers, 2014–2026 · strength 2.64
  10. Samir Hanash · 22 shared papers, 2015–2026 · strength 2.52
  11. Gauri Rajani Varadhachary · 28 shared papers, 1 shared grant, 2014–2025 · strength 2.48
  12. Johannes Francois Fahrmann · 15 shared papers, 2019–2026 · strength 2.29
  13. Ronald Anthony Depinho · 14 shared papers, 1 shared grant, 2016–2026 · strength 2.28
  14. Ching-Wei David Tzeng · 18 shared papers, 2017–2025 · strength 2.21
  15. Ziding Feng · 8 shared papers, 1 shared trial, 1 shared grant, 2018–2026 · strength 2.19
  16. Shubham Pant · 10 shared papers, 1 shared grant, 2019–2026 · strength 2.14
  17. Jimin Min · 9 shared papers, 2023–2026 · strength 2.13
  18. Vincent Bernard · 18 shared papers, 2017–2026 · strength 2.01
  19. Ehsan Irajizad · 12 shared papers, 2020–2026 · strength 1.95
  20. Jeffrey E. Lee · 24 shared papers, 2014–2023 · strength 1.84
  21. Laura R. Prakash · 17 shared papers, 2015–2026 · strength 1.83
  22. Raghu Kalluri · 8 shared papers, 1 shared grant, 2018–2026 · strength 1.82
  23. Marina Pasca di Magliano · 4 shared papers, 1 shared grant, 2023–2026 · strength 1.76
  24. Jody V. Vykoukal · 12 shared papers, 2019–2026 · strength 1.74
  25. Paola A. Guerrero · 14 shared papers, 2019–2026 · strength 1.67

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.